<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>909</ReferenceId>
        <DateLastUpdated>2011-08-23-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10501486</PubmedId>
            <Abstract>Truncated and chimeric lyssavirus glycoprotein (G) genes were used to carry and express non-lyssavirus B and T cell epitopes for DNA-based immunization of mice, with the aim of developing a multivalent vaccine prototype. Truncated G (GPVIII) was composed of the C-terminal half (aa 253-503) of the Pasteur rabies virus (PV: genotype 1) G containing antigenic site III and the transmembrane and cytoplasmic domains. The chimeric G (GEBL1-PV) was composed of the N-terminal half (aa 1-250) of the European bat lyssavirus 1 (genotype 5) G containing antigenic site II linked to GPVIII. Antigenic sites II and III are involved in the induction of virus-neutralizing antibodies. The B cell epitope was the C3 neutralization epitope of the poliovirus type 1 capsid VP1 protein. The T cell epitope was the H2d MHC I-restricted epitope of the nucleoprotein of lymphocytic choriomeningitis virus (LCMV) involved in the induction of both cytotoxic T cell (CTL) production and protection against LCMV. Truncated G carrying foreign epitopes induced weak antibody production against rabies and polio viruses and provided weak protection against LCMV. In contrast, the chimeric plasmid containing various combinations of B and CTL epitopes elicited simultaneous immunological responses against both parental lyssaviruses and poliovirus and provided good protection against LCMV. The level of humoral and cellular immune responses depended on the order of the foreign epitopes inserted. Our results demonstrate that chimeric lyssavirus glycoproteins can be used not only to broaden the spectrum of protection against lyssaviruses, but also to express foreign B and CTL epitopes. The potential usefulness of chimeric lyssavirus glycoproteins for the development of multivalent vaccines against animal diseases and zoonoses, including rabies, is discussed.</Abstract>
            <ArticleYear>1999</ArticleYear>
            <ArticlePages>2343-51</ArticlePages>
            <ArticleTitle>Lyssavirus glycoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccines.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Desmézières</LastName>
                    <ForeName>E</ForeName>
                </Author>
                <Author>
                    <LastName>Jacob</LastName>
                    <ForeName>Y</ForeName>
                </Author>
                <Author>
                    <LastName>Saron</LastName>
                    <ForeName>M F</ForeName>
                </Author>
                <Author>
                    <LastName>Delpeyroux</LastName>
                    <ForeName>F</ForeName>
                </Author>
                <Author>
                    <LastName>Tordo</LastName>
                    <ForeName>N</ForeName>
                </Author>
                <Author>
                    <LastName>Perrin</LastName>
                    <ForeName>P</ForeName>
                </Author>
            </Authors>
            <Affiliations>Laboratoire des Lyssavirus, Institut Pasteur 25, Paris, France.</Affiliations>
            <ArticleChemicalList>Epitopes, B-Lymphocyte;Epitopes, T-Lymphocyte;Recombinant Fusion Proteins;Vaccines, DNA;Viral Envelope Proteins;Viral Vaccines</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Epitopes, B-Lymphocyte; Epitopes, T-Lymphocyte; Female; Lyssavirus(immunology); Mice; Mice, Inbred BALB C; Molecular Sequence Data; Recombinant Fusion Proteins(immunology); T-Lymphocytes, Cytotoxic(immunology); Vaccines, DNA(immunology); Viral Envelope Proteins(immunology); Viral Vaccines(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>80 ( Pt 9)</Volume>
                <Title>The Journal of general virology</Title>
                <Issn>1465-2099</Issn>
                <MedlineTa>J Gen Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>C3</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DNPASTTNKDK</LinearSequence>
                        <StartingPosition>672</StartingPosition>
                        <EndingPosition>682</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>130533</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>138950</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Fig 1</LocationOfData>
                <EpitopeId>9524</EpitopeId>
                <ReferenceStartingPosition>93</ReferenceStartingPosition>
                <ReferenceEndingPosition>103</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitope known to induce neutralizing antibodies against Poliovirus Swiss Prot entry is for viral polyprotein, and epitope position in that entry are related to the entire polyprotein sequence.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>10338</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>DNPASTTNKDK</LinearSequence>
                                            <StartingPosition>672</StartingPosition>
                                            <EndingPosition>682</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>130533</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>138950</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>C3</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>38</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Cells transiently infected with a plasmid encoding for a rabies virus glycoprotein chimera with this epitope sequence inserted, are recognized by mAb directed to the epitope without the need of permeabilization, indicating that it is expressed at the cellular surface. A polyclonal antibody preparation against source species is also shown to recognize the epitope on the cell surface.  Neuro-2a cells were transiently transfected with various plasmids, expressing the chimeric G protein GEBL1-PV with insertion between the ELB1 and PV domains, encoding this epitope and a T cell epitope (named T or t according to its length) from LCMV in different order and as a single or double tandem.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>T-B, B-T, B-t, (B-t)&lt;sub&gt;2&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DNPASTTNKDKLFAVPQASGVYMG</LinearSequence>
                                        <StartingPosition>0</StartingPosition>
                                        <EndingPosition>23</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>130533</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>138950</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Protein conjugate</ComplexType>
                                    <PeptideModifications/>
                                    <SourceMolecule>
                                        <GenBankId>37039492</GenBankId>
                                    </SourceMolecule>
                                    <MoleculeSourceOrganismId>11292</MoleculeSourceOrganismId>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4 and table 2</LocationOfData>
                        <BCellId>10339</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>7 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>DNPASTTNKDK LFAVPQASGVYMGDNPASTTNKDK LFAVPQASGVYMG</LinearSequence>
                                            <StartingPosition>0</StartingPosition>
                                            <EndingPosition>49</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>130533</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>138950</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>(B-t)&lt;sub&gt;2&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>37039492</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>11292</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>1 or 2 doses of 0.1 mg DNA, divided in 2 injections, one in each anterior tibialis muscle. If 2 doses, they were 14 days apart.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with plasmid expressing the C terminal region of glycoprotein from rabies virus (PV) with an insertion at the N-terminus encoding this epitope (B) and a T cell epitope ( t)  from LCMV as a double tandem. Also a rabies virus glycoprotein chimera was assayed, with the epitopes inserted in the middle of the molecule. At different times after immunization, serum was obtained from retroorbital blood and tested for Ab production against epitope.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice immunized with a plasmid encoding a rabies virus glycoprotein chimera or truncation with this epitope sequence inserted, produce antibodies recognizing this epitope, implying this rabies virus protein chimera is able to carry foreign B cell epitopes and induce antibody production. 2 immunizations 14 days apart with the epitope expressing plasmid are shown to be more effective than 1 immunization or than priming with plasmid without epitope followed by a boost with the epitope-containing plasmid.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>C3</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DNPASTTNKDK</LinearSequence>
                                        <StartingPosition>672</StartingPosition>
                                        <EndingPosition>682</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>130533</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>138950</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

